Molnupiravir is the first oral antiviral treatment for Covid to report clinical trial results. The first pill designed to treat symptomatic Covid has been approved by the UK medicines regulator.

Molnupiravir was given to people twice a day, for five days at home, while they had the Omicron variant of Covid. Those chosen were at a higher risk of death or hospitalisation from Covid due to ...

Authorized Use of LAGEVRIO TM (molnupiravir) in the U.S. LAGEVRIO (molnupiravir) is authorized for use under an Emergency Use Authorization (EUA) for the treatment of adults with mild-to-moderate ...

The Emory researchers named their drug molnupiravir, after Mjölnir—the hammer of Thor. It turns out that this was not hyperbole. Last month, Merck and Ridgeback announced that molnupiravir ...

Pfizer’s Paxlovid and Merck & Co’s Molnupiravir are two oral antiviral treatments authorised for patients with mild to moderate COVID-19 symptoms at a high risk of developing severe illness.